RESEARCH DIGEST · THYMOSIN BETA-4
TB-500: What Three Decades of Tissue-Repair Research Have Measured
A considered reading of the published literature on the thymosin beta-4 heptapeptide — mechanism, tissue-repair findings, cardiac and neuroprotective data, and the open questions, with every quantitative claim cited.
What the TB-500 Literature Has Demonstrated
TB-500 is a synthetic seven-amino-acid peptide (Ac-LKKTETQ) corresponding to the active actin-binding fragment of thymosin beta-4 — a 44-amino-acid endogenous protein present in virtually every human and animal cell [6]. The peptide spans amino acids 17–23 of the parent protein and retains the central G-actin sequestering domain that gives thymosin beta-4 its primary biological activity.
The research record spans wound closure, tendon and ligament repair, cardiac progenitor activation, angiogenesis, inflammation modulation, and neuroprotection. Across rodent models, thymosin beta-4 applied topically or intraperitoneally increased wound reepithelialization by 42% at day 4 and 61% at day 7 compared to saline controls [2]. The same studies documented 2–3-fold stimulation of keratinocyte migration at concentrations as low as 10 pg in Boyden chamber assays [2]. In ligament repair, 1 µg Tβ4 delivered in fibrin sealant to transected rat medial collateral ligaments produced uniform, evenly-spaced fiber bundles with significantly increased collagen fibril diameters at four weeks [10].
Thymosin beta-4 is the first molecule identified capable of simultaneously initiating myocardial and vascular regeneration following cardiac injury in a mouse model [5]. It activated endogenous cardiac progenitors, inhibited myocardial cell death, and stimulated vessel growth in a single systemic administration [5].
TB-500 is not FDA-approved for any human indication. It is listed by WADA under Section S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — and is prohibited at all times in sanctioned sport [1]. The heptapeptide has not been evaluated in a published randomized controlled trial in humans; Phase I safety data exist for the full-length 44-amino-acid thymosin beta-4 protein, which is a distinct molecule [11][12]. This site documents the published research. It does not offer clinical services, does not sell any product, and does not make recommendations for human use.
What Is TB-500?
TB-500 is the synthetic N-acetylated heptapeptide Ac-LKKTETQ, corresponding to amino acids 17–23 of thymosin beta-4. The seven-residue sequence — leucine, lysine, lysine, threonine, glutamic acid, threonine, glutamine — constitutes the actin-binding active site of the parent protein. TB stands for thymosin beta; the 500 designation reflects the compound's identity as the synthetic active-site fragment [1].
Thymosin beta-4 itself is one of the most abundant intracellular peptides in mammalian cells: released by platelets and macrophages during tissue injury, it orchestrates a cascade of repair events including reduced apoptosis, reduced microbial growth, stem and progenitor cell mobilization, angiogenesis, and anti-inflammatory signaling [6]. TB-500 retains most of these activities in the compact seven-amino-acid sequence [6].
The compound was first formally characterized in anti-doping research: a 2012 LC-MS/MS study identified TB-500 and its metabolites in equine plasma at 0.02 ng/mL and urine at 0.01 ng/mL following a single 10 mg dose, establishing the analytical identity of Ac-LKKTETQ as the active fragment in biological samples [1].
TB-500 Peptide: Synthetic Fragment of Thymosin Beta-4
The relationship between TB-500 and thymosin beta-4 is that of a defined fragment to its parent: TB-500 is the minimal active-site sequence that reproduces most of the parent protein's actin-sequestering and cell-migration-promoting activity [6]. The full 44-amino-acid thymosin beta-4 has been studied in Phase I human trials; TB-500 (Ac-LKKTETQ specifically) has not yet reached that stage, though it shares the key biochemical domain [11][12].
The peptide's molecular weight is 799.9 Da. It is water-soluble, susceptible to proteolytic degradation in the gastrointestinal tract, and studied in research protocols using parenteral administration — subcutaneous or intramuscular injection in equine and informal clinical-adjacent contexts, and intraperitoneal or intravenous routes in animal models.
For comparative context on the TB-500 vs BPC-157 question — the two most frequently co-discussed research peptides in tissue-repair literature — see the research section.
What Is TB-500 Used For in Research?
The published preclinical record covers five principal areas:
Wound healing and tissue repair. Topical and systemic thymosin beta-4 accelerated full-thickness wound closure by 42–61% over controls at days 4–7 in rat models, with parallel increases in collagen deposition and angiogenesis [2]. Tendon and ligament repair studies show superior fiber organization and increased collagen fibril diameter at injury sites [10]. Skin flap survival — a proxy for tissue viability following surgical reconstruction — improved dose-dependently at 2–10 mg/kg/day in rat models via Wnt/β-catenin activation [20].
Cardiac repair. Thymosin beta-4 activated endogenous epicardial progenitors and simultaneously drove myocardial and vascular regeneration in murine models of cardiac injury [5]. In a large-animal porcine model, TB4 co-delivered with iPSC-derived cardiomyocytes improved left ventricular ejection fraction, reduced infarct size, and enhanced cell engraftment fivefold compared to cell therapy alone [16].
Angiogenesis. VEGF upregulation and VEGFR2 activation are the primary angiogenic signaling outputs of TB-500; these have been characterized across wound, cardiac, and ischemic tissue models [7].
Neuroprotection. At doses of 6 and 30 mg/kg IP in rats with traumatic brain injury, thymosin beta-4 initiated 6 hours post-injury improved sensorimotor function, reduced cortical lesion volume, reduced hippocampal cell loss, and enhanced neurogenesis — the 30 mg/kg dose showing superior outcomes [14].
Hair follicle biology. Thymosin beta-4 activates follicle stem cells in the bulge region, stimulates their migration and differentiation, and upregulates MMP-2; transgenic overexpressing mice show faster hair regrowth than wild-type, and knockouts show slower [8].
For the full TB-500 dosage context from published protocols, and for the documented TB-500 side effects reported in research, see the dedicated sections.
Is TB-500 a Steroid?
No. TB-500 is a synthetic peptide — seven amino acids — structurally and mechanistically unrelated to anabolic-androgenic steroids. It does not bind androgen receptors. Its primary mechanism is G-actin sequestration and VEGF/VEGFR2 upregulation, not hormonal-receptor modulation [6][7]. The two compound classes share only the characteristic of being prohibited by WADA: steroids under S1, TB-500 under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) [1].